During the period 1970 to 1985, 539 constitutionally tail girls were treated with ethinyloestradiol in varying dosages to reduce final height. They ali had a predicted final height above 181 cm (>+2 5 SD). The girls were all healthy and were treated with three different dosages of ethinyloestradiol. Throughout these 15 years recommended treatment regimens changed, and the treatments described foliowed these guidelines. Girls in group 1 (n=263) were treated with 0-5 mg of ethinyloestradiol, group 2 (n=178) with 0-25 mg, and group 3 (n=98) with 0-1 mg. The total mean (SEM) reduction of final height was 5-9 (0.2), 5-3 (0-1), and 4-4 (0.2) cm when treated with 0-5, 0-25, and 0-1 mg respectively. Group 1 was treated for 2-02 (0.03) years and group 2 and 3 for 1-85 (0.04) and 1-63 (0.05) years respectively. When expressed in relation to the treatment period the reduction of final height was 3-0 (0-1), 3-1 (0-1), and 2-9 (0.2) cm/year of treatment respectively. All the girls were treated with ethinyloestradiol as a daily single dose, while progestogen was given daily the first 10 days of every month.In conclusion we found that a daily dose of ethinyloestradiol 0.1 mg for about 20 months is sufficient to reduce final height. We recommend starting treatment at a bone age of about 12 years.

No abstract

ABSTRACT. Purpose: To compare the clinical and bacteriological effects of fucidic acid (FucithalmicA : 1.0%) and chloramphenicol (Minims A : 0.5%) eye drops in neonates with a clinical diagnosis of acute conjunctivitis of suspected bacterial origin. Methods: A total of 456 newborns with gestational age Ͼ 32 weeks with acute conjunctivitis of suspected bacterial origin acquired within the first 28 days of life were included in the study. They were randomly assigned to a 7-day treatment with eye drops using either fucidic acid (1.0%) (Fucithalmic A ) applied twice per day, or chloramphenicol (0.5%) (Minims A Chloramphenicol) applied six times per day. The subjects were followed up with two visits (on days 1 and 8) and by telephone 2 weeks after the end of treatment. Results: Eighty-nine per cent of the neonates treated with FucithalmicA were cured, compared to 87.9% of those treated with Minims A Chloramphenicol (n.s). The drug was used as instructed in 90.7% of patients treated with Fucithalmic A and in 78.0% of those treated with Minims A Chloramphenicol (P ∞ 0.001). Conclusion: Treating neonatal conjunctivitis with fucidic acid is easier than with chloramphenicol and is equally effective.

Campomelic dysplasia (CD) is a rare skeletal dysplasia. The incidence, reported in the literature, is 0.05-0.09 per 10,000 live births. During the period December 1985-December 1990 there were 18,350 live births with 4 cases of CD at Aker University Hospital in Oslo, Norway. This gives an incidence of CD in our observation period of 2.2 per 10,000. Eliminating our first case, because of Pakistani decent, the total incidence is 1.6 per 10,000 among Norwegian infants which is much higher than the incidence previously mentioned. Perhaps CD is under-reported and a high proportion of patients remain undiagnosed. We present four cases and discuss the incidence.

No abstract